- UNDER STRICT EMBARO UNTIL TUESDAY, 28 APRIL - ESCMID announces late-breaking study results at ECCMID Five abstracts presenting evidence on the efficacy of a new herpes zoster vaccine, a study on renal failure rates, a - Herpes zoster - Document - PDFSEARCH.IO

First Page	Meta Content
	- UNDER STRICT EMBARO UNTIL TUESDAY, 28 APRIL - ESCMID announces late-breaking study results at ECCMID Five abstracts presenting evidence on the efficacy of a new herpes zoster vaccine, a study on renal failure rates, a Add to Reading List Document Date: 2015-04-27 03:08:17 Open Document File Size: 295,71 KB Share Result on Facebook City Copenhagen / / Company Cempra Inc. / GlaxoSmithKline plc / IGNITE1 Tetraphase Pharmaceutical Inc. / / Country Switzerland / Brazil / / MedicalCondition uncomplicated urinary tract infections / S. aureus / community-acquired bacterial pneumonia / bacterial pneumonia / herpes zoster / pyelonephritis / potential immune-mediated diseases / renal failure / intra-abdominal infections / infections / infectious disease / / MedicalTreatment salvage therapy / oral therapy / / Organization ECCMID / ESCMID Programme Committee / European Society of Clinical Microbiology and Infectious Disease / / Person Winfried Kern / / Position programme Director / / Product colistimethate / norfloxacin / / SocialTag Viral diseases Vaccination Chickenpox Herpesviruses Infectious diseases Moxifloxacin Diclofenac Herpes zoster Norfloxacin Organic chemistry

- UNDER STRICT EMBARO UNTIL TUESDAY, 28 APRIL - ESCMID announces late-breaking study results at ECCMID Five abstracts presenting evidence on the efficacy of a new herpes zoster vaccine, a study on renal failure rates, aAdd to Reading List